Edition:
India

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

4.23USD
23 Apr 2018
Change (% chg)

$0.03 (+0.71%)
Prev Close
$4.20
Open
$4.20
Day's High
$4.34
Day's Low
$4.15
Volume
22,298
Avg. Vol
41,540
52-wk High
$5.53
52-wk Low
$3.13

Chart for

About

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $238.49
Shares Outstanding(Mil.): 50.53
Dividend: --
Yield (%): --

Financials

  FBIO.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.48 -- --
ROI: -84.71 14.84 14.38
ROE: -111.07 16.34 16.07

BRIEF-Mustang Bio Reports Q4 Financial Results

* MUSTANG BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

30 Mar 2018

BRIEF-Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial

* MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL

12 Dec 2017

BRIEF-Fortress Biotech forms subsidiary Tamid Bio to develop novel aav gene therapies in Orphan Diseases

* FORTRESS BIOTECH FORMS SUBSIDIARY TAMID BIO TO DEVELOP NOVEL AAV GENE THERAPIES IN ORPHAN DISEASES WITH UNMET MEDICAL NEEDS Source text for Eikon: Further company coverage:

05 Dec 2017

BRIEF-Mustang Bio names new vice president of finance and corporate controller

* Mustang Bio announces appointment of Brian Achenbach as vice president of finance and corporate controller Source text for Eikon: Further company coverage:

14 Nov 2017

BRIEF-Fortress Biotech posts Q3 loss per share $0.67

* Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights

10 Nov 2017

BRIEF-Fortress Biotech announces pricing of series a preferred stock offering

* Fortress Biotech Inc announces pricing of series a preferred stock offering

07 Nov 2017

BRIEF-Fortress Biotech proposes public offering of Series A preferred stock

* Fortress Biotech announces proposed public offering of Series A preferred stock Source text for Eikon: Further company coverage:

01 Nov 2017

BRIEF-Mustang Bio enters lease agreement for production of Car T therapies

* Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​

30 Oct 2017

Earnings vs. Estimates